Borlak, DE
Jurgen Borlak, Hannover DE
Patent application number | Description | Published |
---|---|---|
20100008935 | METHOD FOR IDENTIFYING THERAPEUTICAL TARGETS IN TUMORS, THE USE THEREOF AND MEANS FOR DETERMINING AND TARGETING ANGIOGENESIS AND HEMOSTASIS RELATED TO ANDENOCARCINOMAS OF THE LUNG - Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF/SF) are potent mitogens with proven angiogenic activities in human and animal disease models. These growth factors display little overlap in angiogenesis signaling cascades. The application reports angiogenesis in lung adenocarcinomas to be coordinated by hemostatic events. The invention relates to a method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, the use of novel targets for identifying, determining, and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung, and the use of the therapeutical targets identified for screening and determining means and/or drugs. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies. Furthermore the aim is the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, determining and treating angiogenesis and hemostasis related to adenocarcinomas, in particular of advanced stage tumors of the lung. The method for identifying therapeutical targets in tumors, in particular in advanced stage tumor malignancies, comprising the steps of—isolating RNA (1) from the tissue of the tumor; —determining for the isolated RNA (1) a gene expression profile (2) of at least two genes, wherein at least one gene (3) is coding for a VEGF activity modulator and at least one gene (4) is coding for a hemostatic factor by screening the presence of mRNA coding for the factors to be screened and by determining the levels of expression of thereof; —determining the changes of expression of the at least two genes screened by the gene expression profile (2) in comparison with healthy tissue or with an early stage tumor; and—identifying the therapeutical target as a hemostatic factor, being upregulated or down-regulated. | 01-14-2010 |
Jurgen Borlak, Lehrte/immensen DE
Patent application number | Description | Published |
---|---|---|
20130078255 | SERUM AND TISSUE BIOMARKERS OF HUMAN HCC - The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group consisting of Polymeric immunoglobulin receptor, Phosphatidylinositol—glycan—specific phospholipase D, Alpha—fetoprotein, Antithrombin 3, Apolipoprotein E, Apolipoprotein M, Fibrinogen beta-chain, Haptoglobin, Paraoxonase 1, Retinol binding protein, Serum amyloid P- component, Transthyretin, or from a second group consisting of Afamin, Glutathione peroxidase 3, Hemopexin, Major urinary protein, Serine protease inhibitor A3K. Consequently, medical uses of said proteins, of corresponding compositions, of corresponding antibodies, of corresponding siRNA and of corresponding nucleotide sequences are claimed. Also claimed are corresponding kits and corresponding methods and procedures. | 03-28-2013 |
20130183737 | NOVEL BIOMARKERS OF LIVER CANCER - The invention is based on the surprising finding that proteins regulated by excessive EGFR signalling in the liver may be used as biomarkers in the diagnosis, prognosis and/or monitoring of treatment of diseases, including liver cell dysplasia or hepatocellular carcinoma (HCC), wherein the protein is selected from a first group consisting of Arginase type II, 4931406C07Rik (Ester hydrolase C11orf54 homolog), Akr1c12 protein, Alanyl-tRNA synthetase, Aldo-keto reductase family 1 member C14, Aldo-keto reductase family 1 member C6, Aldolase 3, Alpha glucosidase 2, Beta 5-tubulin, Cai protein (Pdia4), cDNA sequence BC021917 (dihydroxyacetone kinase 2 homolog), Farnesyl diphosphate synthetase, Fatty acid binding protein 5 epidermal, Inosine triphosphatase, Interleukin 25, Kininogen 1, LIM and SH3 protein 1, Major vault protein, Nucb1 protein, Poly(rC) binding protein 2; heterogeneous nuclear ribonucleoprotein X, Psmd11 protein, RIKEN cDNA 2410004H02, Rps12 protein, Sars1 protein, Sorcin, T43799 proteasome protein p45/SUG [imported], Uap1 l1 protein, v-crk sarcoma virus CT10 oncogene homolog, and 170 kDa glucose regulated protein GRP170 precursor, or from a second group consisting of 2-hydroxyphytanoyl-CoA lyase, Branched chain ketoacid dehydrogenase E1 alpha polypeptide; Butyryl Coenzyme A synthetase 1, Dhdh protein, Diacetyl/L-xylulose reductase, Dmgdh protein (Dimethylglycine dehydrogenase, mitochondrial), Enoyl coenzyme A hydratase 1 peroxisomal, Hypothetical protein LOC68347, Lysophospholipase 1, Mitochondrial acyl-CoA thioesterase 1, PREDICTED: agmatine ureohydrolase (agmatinase), RIKEN cDNA 1810013B01 (abhydrolase domain containing 14b), and Serpinb1a protein. Based on this finding novel biomarkers and molecules binding to said biomarkers, compositions and a kit, as well as methods for the diagnosis, prognosis and/or monitoring of treatment of dysplasia and cancer patients, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC) patients are provided according to the invention. | 07-18-2013 |
Jurgen Borlak, Lehrte DE
Patent application number | Description | Published |
---|---|---|
20090036348 | Use of Novel HNF4a Target Genes and Their Gene Products - Dysfunction of HNF4α may lead to disease and an identification of genes targeted by this factor provides insights into mechanisms of disease. In accordance with the invention thirteen new HNF4α target genes were found (C20orf13, KIAA0774, EPS15R, PLCB1, UGTREL1, RSK4, PAK5, FMR2, NEB, NFYC, KCNQ4, PRPF3, TRPC1). These genes were identified by means of molecular biological and molecular genetic methods. The genes code for various biological functions (metabolism, regulation of cell cycle and signal transduction, differentiation, ion channels, mRNA processing, see table A) and are thus important for the therapy of metabolic disorders, diabetic diseases and tumor growth. In the present invention, additionally eleven new HNF4α target genes are described. It was shown that HNF4α and TPRC1 are regulated in animal models of diabetes. Thus, TPRC1 is a candidate gene for the treatment of diabetic nephropathy. The discovery of the above described target genes of HNF4α and their function comprises an enormous potential for the treatment of metabolic discuses including diabetes and diabetic caused diseases and tumor growth. | 02-05-2009 |
20100249152 | NEW 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO[3,4-D PYRIMIDINE AND PYRROLO[2,3-D]PYRIMIDINE AND USES THEREOF - The present invention relates to a compound 4-substituted derivative of pyrazolo[3,4-d]pyrimidine or of pyrrolo[2,3-d]pyrimidine having the formula (I) and uses thereof, in particular for the treatment of bone related diseases and tumours. | 09-30-2010 |
Jürgen Borlak, Lehrte Ot Immensen DE
Patent application number | Description | Published |
---|---|---|
20110064652 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG - The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 03-17-2011 |
20110082089 | BIOMARKERS FOR MONITORING OR PREDICTING THE TREATMENT OF CANCER - We provide for the diagnosis, prognosis and/or treatment monitoring of lung cancer or bronchial dysplasia, and the use thereof for predicting and monitoring therapeutic intervention in dysplasia or cancer patients. According to the invention at least one biomarker selected from the group consisting of APOE, APOC3, A1AT6, A2MG, PROP, TTHY, A1AG8, APOA1, APOH, GPX3, MUP8, RETBP, SAMP, VTDB, S6A11, EGFR, ApoA4, ApoM, a-raf, fetuin B, GSN, PLG, VPS28, and particular peptide sequences derived thereof, is used in the diagnosis, prognosis and/or treatment monitoring of cancer or dysplasia, in particular of lung cancer or the level of at least one of said biomarkers is measured in a body fluid sample, in particular in a blood serum sample, of a patient suffering from or being susceptible to cancer or dysplasia. | 04-07-2011 |
Jürgen Borlak, Lehrte Ot Immensen DE
Patent application number | Description | Published |
---|---|---|
20110064652 | NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG - The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 03-17-2011 |
20110082089 | BIOMARKERS FOR MONITORING OR PREDICTING THE TREATMENT OF CANCER - We provide for the diagnosis, prognosis and/or treatment monitoring of lung cancer or bronchial dysplasia, and the use thereof for predicting and monitoring therapeutic intervention in dysplasia or cancer patients. According to the invention at least one biomarker selected from the group consisting of APOE, APOC3, A1AT6, A2MG, PROP, TTHY, A1AG8, APOA1, APOH, GPX3, MUP8, RETBP, SAMP, VTDB, S6A11, EGFR, ApoA4, ApoM, a-raf, fetuin B, GSN, PLG, VPS28, and particular peptide sequences derived thereof, is used in the diagnosis, prognosis and/or treatment monitoring of cancer or dysplasia, in particular of lung cancer or the level of at least one of said biomarkers is measured in a body fluid sample, in particular in a blood serum sample, of a patient suffering from or being susceptible to cancer or dysplasia. | 04-07-2011 |
20110136137 | SERUM PROTEOMIC FOR FINDING DIAGNOSTIC MARKERS AND FOR MONITORING THERAPEUTICAL INTERVENTION IN TREATMENT OF HEPATOCELLULAR CARCINOMA - The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. | 06-09-2011 |
Jürgen Borlak, Lehrte DE
Patent application number | Description | Published |
---|---|---|
20090036348 | Use of Novel HNF4a Target Genes and Their Gene Products - Dysfunction of HNF4α may lead to disease and an identification of genes targeted by this factor provides insights into mechanisms of disease. In accordance with the invention thirteen new HNF4α target genes were found (C20orf13, KIAA0774, EPS15R, PLCB1, UGTREL1, RSK4, PAK5, FMR2, NEB, NFYC, KCNQ4, PRPF3, TRPC1). These genes were identified by means of molecular biological and molecular genetic methods. The genes code for various biological functions (metabolism, regulation of cell cycle and signal transduction, differentiation, ion channels, mRNA processing, see table A) and are thus important for the therapy of metabolic disorders, diabetic diseases and tumor growth. In the present invention, additionally eleven new HNF4α target genes are described. It was shown that HNF4α and TPRC1 are regulated in animal models of diabetes. Thus, TPRC1 is a candidate gene for the treatment of diabetic nephropathy. The discovery of the above described target genes of HNF4α and their function comprises an enormous potential for the treatment of metabolic discuses including diabetes and diabetic caused diseases and tumor growth. | 02-05-2009 |
Jürgen Borlak, Lehrte/immensen DE
Patent application number | Description | Published |
---|---|---|
20130078255 | SERUM AND TISSUE BIOMARKERS OF HUMAN HCC - The application is based on the surprising finding that proteins regulated by increased c-myc activity in the liver can be used as sis and/or treatment monitoring of cancer and dysplasia, in particular of liver cell dysplasia and hepatocellular carcinoma (HCC), and wherein the proteins are selected from a first group consisting of Polymeric immunoglobulin receptor, Phosphatidylinositol—glycan—specific phospholipase D, Alpha—fetoprotein, Antithrombin 3, Apolipoprotein E, Apolipoprotein M, Fibrinogen beta-chain, Haptoglobin, Paraoxonase 1, Retinol binding protein, Serum amyloid P- component, Transthyretin, or from a second group consisting of Afamin, Glutathione peroxidase 3, Hemopexin, Major urinary protein, Serine protease inhibitor A3K. Consequently, medical uses of said proteins, of corresponding compositions, of corresponding antibodies, of corresponding siRNA and of corresponding nucleotide sequences are claimed. Also claimed are corresponding kits and corresponding methods and procedures. | 03-28-2013 |
JÜrgen Borlak, Lehrte/ot Immensen DE
Patent application number | Description | Published |
---|---|---|
20090221444 | Method for Identifying, Marking and Treating Epithelial Lung Tumour Cells and Means for Carrying Out Said Method - The bronchial carcinoma is the most common tumour found in humans world-wide and is in most cases beyond remedy. The invention relates to a method for identifying, marking and treating epithelial lung tumour cells, specifically of an adenocarcinoma, with the aid of novel treatment targets, and to means for carrying out said method. At the basis of the invention is the discovery that the expression of genes that code for CAM and ECM molecules is modified in c-raf and/or c-myc induced adenocarcinomas of the lung. Cell-adhesion proteins and extra-cellular matrix proteins constitute the treatment targets. According to the invention, a biological or biotechnological system is brought into contact with a dissolved substance that has an affinity to at least one of the following genes: ADAM19, Mmp12, Col18a1, Col15a1, CD44, Bsg, Itgb2, Itgax, Lamc2, Lamb3, Alcam, Cldn2, Cldn3, Cldn7, Krt1-18, Krt2-8, tacstd1, tacstd2, S100a1, S100a11, their variants, parts of said genes, their mRNA or their gene products, cleavage products derived from said genes, polypeptides or peptides, said substance being bound to a suitable marker. | 09-03-2009 |
20100069255 | METHOD FOR IDENTIFYING THERAPEUTICAL TARGETS IN SECONDARY TUMORS, THE USE OF THEREOF AND MEANS FOR IDENTIFYING, LABELLING AND TARGETING SECONDARY TUMORS - In comparison with primary tumors, where the organ by itself is the starting point of the malignant degeneration, metastases inherit a different emergence. The molecular causes leading to secondary liver malignancies are unknown so far. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in secondary tumors, the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, labeling and treating secondary metastases in the liver made up of or derived from tumor cells of the colon. In principle, expression of transcription factors is studied in the primary tumor, the secondary tumor and in the healthy organ, wherein the secondary tumor is formed, according to the invention, in particular of transcription factors being enriched in the healthy tissue of the organ, wherein the secondary tumor is formed, e.g. expression of liver enriched transcription factors HNF6 and/or Foxa2 or of NGN3, HSP105B, HSP10, HNF1β, C/EBP is studied, such as by reverse transcription polymerase chain reaction, by gene chip analysis, by Western blotting technique, by studying the DNA binding of liver enriched transcription factors by electromobility shift assay (EMSA) or by genomic sequencing of therapeutical targets, such as of HNF6. | 03-18-2010 |
20110064739 | MEDICAMENT, COMPOSITIONS, AND SUBSTANCES FOR TREATING AND IDENTIFYING ADENOCARCINOMA OF THE LUNG - The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung. | 03-17-2011 |
20130136688 | Nanoparticles for Targeted Delivery of Active Agents to the Lung - The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 05-30-2013 |
JÜrgen Borlak, Lehrte/ot Immensen DE
Patent application number | Description | Published |
---|---|---|
20090221444 | Method for Identifying, Marking and Treating Epithelial Lung Tumour Cells and Means for Carrying Out Said Method - The bronchial carcinoma is the most common tumour found in humans world-wide and is in most cases beyond remedy. The invention relates to a method for identifying, marking and treating epithelial lung tumour cells, specifically of an adenocarcinoma, with the aid of novel treatment targets, and to means for carrying out said method. At the basis of the invention is the discovery that the expression of genes that code for CAM and ECM molecules is modified in c-raf and/or c-myc induced adenocarcinomas of the lung. Cell-adhesion proteins and extra-cellular matrix proteins constitute the treatment targets. According to the invention, a biological or biotechnological system is brought into contact with a dissolved substance that has an affinity to at least one of the following genes: ADAM19, Mmp12, Col18a1, Col15a1, CD44, Bsg, Itgb2, Itgax, Lamc2, Lamb3, Alcam, Cldn2, Cldn3, Cldn7, Krt1-18, Krt2-8, tacstd1, tacstd2, S100a1, S100a11, their variants, parts of said genes, their mRNA or their gene products, cleavage products derived from said genes, polypeptides or peptides, said substance being bound to a suitable marker. | 09-03-2009 |
20100069255 | METHOD FOR IDENTIFYING THERAPEUTICAL TARGETS IN SECONDARY TUMORS, THE USE OF THEREOF AND MEANS FOR IDENTIFYING, LABELLING AND TARGETING SECONDARY TUMORS - In comparison with primary tumors, where the organ by itself is the starting point of the malignant degeneration, metastases inherit a different emergence. The molecular causes leading to secondary liver malignancies are unknown so far. The aim of the present invention is therefore to make available an easy and efficient method for identifying therapeutical targets in secondary tumors, the use of novel therapeutical targets identified by the method for screening and determining beneficial means and/or drugs, and means and drugs for identifying, labeling and treating secondary metastases in the liver made up of or derived from tumor cells of the colon. In principle, expression of transcription factors is studied in the primary tumor, the secondary tumor and in the healthy organ, wherein the secondary tumor is formed, according to the invention, in particular of transcription factors being enriched in the healthy tissue of the organ, wherein the secondary tumor is formed, e.g. expression of liver enriched transcription factors HNF6 and/or Foxa2 or of NGN3, HSP105B, HSP10, HNF1β, C/EBP is studied, such as by reverse transcription polymerase chain reaction, by gene chip analysis, by Western blotting technique, by studying the DNA binding of liver enriched transcription factors by electromobility shift assay (EMSA) or by genomic sequencing of therapeutical targets, such as of HNF6. | 03-18-2010 |
20110064739 | MEDICAMENT, COMPOSITIONS, AND SUBSTANCES FOR TREATING AND IDENTIFYING ADENOCARCINOMA OF THE LUNG - The invention is based on the finding that in mammalian lungs c-myc acts as a molecular switch, specifically inducing an expression pattern in vivo, which results in prototypical mammalian adenocarcinoma of the lung and liver metastasis. A set of factors essential for the processes of tumorigenesis and tumor progression, i.e. cell cycle and apoptosis, cell growth, extracellular signaling, angiogenesis and invasion, is identified, whose expression is significantly changed. In particular, the expression pattern found uncovers the network of molecules leading to mammalian papillary adenocarcinomas of the lung. | 03-17-2011 |
20130136688 | Nanoparticles for Targeted Delivery of Active Agents to the Lung - The present invention concerns a delivery system administered to the lung preferably by inhalation comprising a polymer-based nanoparticle; and a linker comprising a first portion non-covalently anchored to said nanoparticle, wherein at least part of said first portion comprises a hydrophobic/lipophilic segment embedded in said nanoparticle; and a second portion comprising a coupling group, preferably a maleimide compound, exposed at the outer surface of said nanoparticle. In accordance with one embodiment, the delivery system comprises one or more targeting agents, each covalently bound to said coupling group, preferably maleimide compound, and is administered as an aerosol in the therapy or diagnosis of lung cancer or bronchial dysplasia. In accordance with yet another embodiment, the delivery system comprises a drug and/or a radiopharmaceutical and/or a contrasting agent. A specific example for a linker in accordance with the invention is octadecyl-4-(maleimideomethyl)cyclohexane-carboxylic amide (OMCCA). | 05-30-2013 |